Compare Heron Therapeutics Inc (HRTX) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Oxford Lane Capital Corp — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M). The key difference: Oxford Lane Capital Corp is far larger — about 12.3× Heron Therapeutics Inc's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Oxford Lane Capital Corp for 50 Days on average.
| HRTX | OXLC | |
|---|---|---|
Market Cap | $68.01M | $835.71M |
Volume | 1,891,941 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $1.49 | $16.74 |
52-Week Low | $0.27 | $8.15 |
Typical Hold Time | 35 Days | 50 Days |
Enterprise Value | $174.75M | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
OXLC trades at $8.56, up 1.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows a low P/B of 0.81 and pays a consistent $0.20 monthly dividend. However, recent earnings have significantly missed expectations, with a Q1 2026 loss of -$6.23 per share, and 2026 revenue and net profit trends are deeply negative, raising sustainability concerns.
The outlook is highly speculative. The deep discount to book value and high dividend yield present a potential value opportunity for income-focused investors, but this is offset by severe profitability erosion, negative cash flow from operations, and analyst skepticism. Key risks include the company's ability to stabilize its net asset value and fund its dividend without further capital erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
